Koen van de Ven

Koen van de Ven

Auto-generated profile, based on publicly available information

Koen van de Ven

Centre for infectious disease control, National institute for public health and the environment (RIVM), Bilthoven, the Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Science Advances
Verified
Journal Article
Open access
KVKoen van de Ven
Koen van de Ven
JLJosien Lanfermeijer
Josien Lanfermeijer
HDHarry van Dijken
Harry van Dijken
HMHIROMI MURAMATSU
HIROMI MURAMATSU
CMCaroline Vilas Boas de Melo
Caroline Vilas Boas de Melo
JJJorgen De Jonge
Jorgen De Jonge
Universal influenza vaccines should protect against continuously evolving and newly emerging influenza viruses. T cells may be an essential target of such vaccines, as they can clear infected cells through recognition of conserved influenza virus epitopes. We evaluated a novel T cell–inducing nucleoside-modified messenger RNA (mRNA) vaccine that encodes the conserved nucleoprotein, matrix protein 1, and polymerase basic protein 1 of an H1N1 influenza virus. To mimic the human situation, we applied the mRNA vaccine as a prime-boost regimen in naïve ferrets (mimicking young children) and as a booster in influenza-experienced ferrets (mimicking adults). The vaccine induced and boosted broadly reactive T cells in the circulation, bone marrow, and respiratory tract. Booster vaccination enhanced protection against heterosubtypic infection with a potential pandemic H7N9 influenza virus in influenza-experienced ferrets. Our findings show that mRNA vaccines encoding internal influenza virus proteins represent a promising strategy to induce broadly protective T cell immunity against influenza viruses.

16 September 2022 in iScience
Verified
Journal Article
Open access
AWArnika K. Wagner
Arnika K. Wagner
NKNadir Kadri
Nadir Kadri
CTChris Tibbitt
Chris Tibbitt
KVKoen van de Ven
Koen van de Ven
SBSunitha Bagawath-Singh
Sunitha Bagawath-Singh
BCBenedict J. Chambers
Benedict J. Chambers
Although PD-1 was shown to be a hallmark of T cells exhaustion, controversial studies have been reported on the role of PD-1 on NK cells. Here, we found by flow cytometry and single cell RNA sequencing analysis that PD-1 can be expressed on MHC class I-deficient tumor-infiltrating NK cells in vivo. We also demonstrate distinct alterations in the phenotype of PD-1-deficient NK cells and a more mature phenotype which might reduce their capacity to migrate and kill in vivo. Tumor-infiltrating NK cells that express PD-1 were highly associated with the expression of CXCR6. Furthermore, our results demonstrate that PD-L1 molecules in membranes of PD-1-deficient NK cells migrate faster than in NK cells from wild-type mice, suggesting that PD-1 and PD-L1 form cis interactions with each other on NK cells. These data demonstrate that there may be a role for the PD-1/PD-L1 axis in tumor-infiltrating NK cells in vivo.

9 October 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
KVKoen van de Ven
Koen van de Ven
FHFemke de Heij
Femke de Heij
HDHarry van Dijken
Harry van Dijken
JFJosé A. Ferreira
José A. Ferreira
JJJorgen De Jonge
Jorgen De Jonge
Traditional influenza vaccines primarily induce a narrow antibody response that offers no protection against heterosubtypic infections. Murine studies have shown that T cells can protect against a broad range of influenza strains. However, ferrets are a more potent model for studying immune correlates of protection in influenza infection. We therefore set out to investigate the role of systemic and respiratory T cells in the protection against heterosubtypic influenza A infections in ferrets. H1N1-priming induced systemic and respiratory T cells that responded against pandemic H2N2 and correlated with reduced viral replication and disease. CD8-positive T cell responses in the upper and lower respiratory tract were exceptionally high. We additionally confirmed that H2N2-responsive T cells are present in healthy human blood donors. These findings underline the importance of the T cell response in influenza immunity and show that T cells are a potent target for future universal influenza vaccines.

21 December 2022 in Microbiology Spectrum
Verified
Journal Article
Open access
CMCaroline Vilas Boas de Melo
Caroline Vilas Boas de Melo
FPFlorence Peters
Florence Peters
HDHarry van Dijken
Harry van Dijken
SLStefanie Lenz
Stefanie Lenz
KVKoen van de Ven
Koen van de Ven
JJJorgen De Jonge
Jorgen De Jonge
During the COVID-19 pandemic, the use of face masks, social distancing, and isolation were effective not only in decreasing the circulation of SARS-CoV-2 but also in reducing other respiratory viruses, such as influenza. With fewer restrictions currently in place, influenza is slowly returning.

27 July 2022 in Journal of Virology
Verified
Journal Article
Open access
KVKoen van de Ven
Koen van de Ven
HDHarry van Dijken
Harry van Dijken
WDWenjuan Du
Wenjuan Du
FHFemke de Heij
Femke de Heij
JMJustin Mouthaan
Justin Mouthaan
JJJorgen De Jonge
Jorgen De Jonge
In 1957 the world was subjected to a pandemic caused by an influenza A virus of the subtype H2N2. Although the virus disappeared in 1968, H2 viruses continue to circulate in avian reservoirs.

12 August 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
JLJosien Lanfermeijer
Josien Lanfermeijer
KVKoen van de Ven
Koen van de Ven
HDHarry van Dijken
Harry van Dijken
MHMarion Hendriks
Marion Hendriks
COCami M. P. Talavera Ormeño
Cami M. P. Talavera Ormeño
JJJorgen De Jonge
Jorgen De Jonge
CD8 + T cells are promising targets for vaccination against influenza A virus (IAV) infection. Their induction via peptide vaccination is not trivial, because peptides are weakly immunogenic. One strategy to overcome this is by vaccination with chemically enhanced altered peptide ligands (CPLs), which have improved MHC-binding and immunogenicity. It remains unknown how peptide-modification affects the resulting immune response. We studied the effect of CPLs derived from the influenza M158–66 epitope (GILGFVFTL) on the T-cell response. In HLA-A2*0201 transgenic mice, CPL-vaccination led to higher T-cell frequencies, but only a small percentage of the induced T cells recognized the GILG-wildtype (WT) peptide. CPL-vaccination resulted in a lower richness of the GILG-WT-specific T-cell repertoire and no improved protection against IAV-infection compared to GILG-WT peptide-vaccination. One CPL even appeared to enhance pathology after IAV-challenge. CPL-vaccination thus induces T cells not targeting the original peptide, which may lead to potential unwanted side effects.